Priya Marreddy
Chief Tech/Sci/R&D Officer at CONTEXT THERAPEUTICS INC.
Profile
Priya Marreddy is currently the Vice President-Clinical Operations at Context Therapeutics, Inc. Previously, she worked as the Head-Clinical Operations at Cornerstone Pharmaceuticals, Inc. She completed her graduate degree at the University of Pennsylvania and her undergraduate degree at George Washington University.
Priya Marreddy active positions
| Companies | Position | Start |
|---|---|---|
| CONTEXT THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 31/03/2022 |
Former positions of Priya Marreddy
| Companies | Position | End |
|---|---|---|
Cornerstone Pharmaceuticals, Inc.
 Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Chief Tech/Sci/R&D Officer | - |
Training of Priya Marreddy
| University of Pennsylvania | Graduate Degree |
| George Washington University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CONTEXT THERAPEUTICS INC. | Health Technology |
| Private companies | 1 |
|---|---|
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Commercial Services |
- Stock Market
- Insiders
- Priya Marreddy
